2. >>Products

Amneal Insists Generics Are Sustainable As It Eyes Further Growth Avenues

Injectables, Biosimilars Push Set To Add To Respiratory And Naloxone Opportunities

 
• By Dean Rudge

Amneal trumpeted its continued faith in the retail generics market at the recent J.P. Morgan Healthcare Conference, as the US-based player also discussed longer-term goals for its burgeoning injectables and biosimilars portfolios.

• Source: Shutterstock

Amneal says it is “probably the only company that can say our retail generics business grew over [the last] four years,” even at a “modest” 2-3%, as the US-based player eyes high-single-

digit growth for its overall top line in the coming years amid a greater push towards complex products and the growth of its other

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products